Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pharmacogenetic-guided prescribing can lead to more accurate medicine selection and dosing, improving patient outcomes and leading to better use of health care budgets. Loss-of-function variants in CYP2C19 influence an individual's ability to metabolize clopidogrel, increasing the risk of secondary vascular events following ischemic stroke and percutaneous coronary intervention. In acute clinical contexts, centralized laboratory-based testing is too slow to inform timely clinical decision-making. This work reports the development and analytical validation of the Genedrive CYP2C19 ID Kit, which provides rapid point-of-care genotyping from a buccal swab in approximately 1 hour. Buccal samples were collected from a total of 204 individuals between September 2023 and July 2024, alongside a blood or saliva sample for comparison with laboratory testing. In the final cohort of 202 patients, all point-of-care results were concordant with laboratory testing. In this assessment, the sensitivity and specificity of the CYP2C19 ID Kit was 100% (95% CI, 95.0%-100%) and 100% (95% CI, 97.2%-100%), respectively. The failure rate of the CYP2C19 ID Kit was 0.98%. This study confirms the analytical validity of the Genedrive CYP2C19 ID Kit. The Genedrive system is able to provide an accurate, rapid, noninvasive alternative to standard laboratory testing and can be used as a point-of-care test in the clinical environment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179497 | PMC |
| http://dx.doi.org/10.1016/j.jmoldx.2024.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay.
Sci Rep
May 2025
Drug and Poison Centre ( A Unit of Department of Pharmacy Practice), SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamil Nadu, 603203, India.
Proton pump inhibitors (PPIs) are commonly used anti-ulcer agents, known to inhibit CYP2C19, leading to pharmacokinetic drug-drug interactions (DDIs). Ilaprazole is a newer PPI with a distinct pharmacokinetic profile that is predicted to overcome CYP2C19 inhibition. The current study aimed to predict the CYP2C19 inhibitory potential of Ilaprazole versus conventional PPIs (Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole) on CYP2C19 activity using a high-throughput fluorometric assay.
View Article and Find Full Text PDFQuantitative clinical risk assessment of CYP2C, UDP-glucuronosyltransferase, P-glycoprotein induction, and complex drug-drug interactions using TruVivo human hepatocyte triculture platform.
Drug Metab Dispos
April 2025
LifeNet Health, Virginia Beach, Virginia.
Quantitative prediction and clinical risk assessment for induction of drug-metabolizing enzymes and transporters beyond CYP3A has been hindered by low dynamic response in the gold standard hepatocyte monoculture model. A gap in translation of the drug-drug interaction (DDI) potential of a compound is particularly apparent when an inducer also inhibits CYP3A, leading to uncertainty in the potential net clinical outcome for CYP3A substrates. In addition, enzymes such as CYP2C8, CYP2C9, CYP2C19, UGT1A4, and P-glycoprotein, which are coregulated with CYP3A, may result in clinically relevant induction that cannot be derisked by conducting clinical interaction studies with CYP3A substrates.
View Article and Find Full Text PDFDevelopment and Validation of a Rapid Point-of-Care CYP2C19 Genotyping Platform.
J Mol Diagn
March 2025
Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom; Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, United Kingdom. Electronic address: john.mcdermott@m
Pharmacogenetic-guided prescribing can lead to more accurate medicine selection and dosing, improving patient outcomes and leading to better use of health care budgets. Loss-of-function variants in CYP2C19 influence an individual's ability to metabolize clopidogrel, increasing the risk of secondary vascular events following ischemic stroke and percutaneous coronary intervention. In acute clinical contexts, centralized laboratory-based testing is too slow to inform timely clinical decision-making.
View Article and Find Full Text PDF[Personalized therapy for on initial treatment: the initial treatment is the decisive battle].
Zhonghua Yi Xue Za Zhi
June 2022
National Engineering Center for Biochips at Shanghai, Shanghai 201203, China.
As widespread eradication treatment continues, the rate of () antibiotic resistance is increasing. Together with host CYP2C19 gene polymorphisms, coccoid transformation, patient compliance, irregular treatment regimens or empirical repeated eradication therapy by physician, eradication rates have gradually decreased. Personalized treatment is an effective measure to achieve successful eradication of in the initial treatment.
View Article and Find Full Text PDFAnalytical validation of GMEX rapid point-of-care genotyping system for the CHANCE-2 trial.
Stroke Vasc Neurol
June 2021
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Background And Purpose: Rapid genotyping is useful for guiding early antiplatelet therapy in patients with high-risk nondisabling ischaemic cerebrovascular events (HR-NICE). Conventional genetic testing methods used in genotype-guided antiplatelet therapy for patients with HR-NICE did not satisfy the needs of the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE)-2 trial. Therefore, we developed the rapid-genotyping GMEX (point-of-care) system to meet the needs of the CHANCE-2 trial.
View Article and Find Full Text PDF